JAK-STAT信号通路及其抑制剂在特应性皮炎治疗中的应用

JAK-STAT signaling pathway and its inhibitors in the treatment of atopic dermatitis

Janus激酶信号转导和转录激活因子(JAK-STAT)信号通路在特应性皮炎(AD)免疫学通路中起着重要作用,阻断JAK-STAT信号通路的药物,如经典的JAK抑制剂托法替尼、鲁索利替尼等,已逐步应用到AD治疗的临床试验中,并取得较好的疗效。其他对JAK-STAT信号通路有抑制作用的因子,如apamin、dupilumab等也在治疗AD上显示出一定效果。本文对近年来JAK-STAT信号通路及其相关抑制剂研究进行综述。

Janus kinase-signal transducer and activator of transcription(JAK-STAT)signaling pathway plays an important role in immune pathways in atopic dermatitis(AD).Drugs that block the JAK-STAT signaling pathway,such as classic JAK inhibitors tofacitinib,ruxolitinib,etc.,have been gradually applied to the treatment of AD in clinical trials,and good clinical efficacy has been achieved.In addition,other inhibitors of the JAK-STAT signaling pathway,such as apamin and dupilumab,also show some efficacy in the treatment of AD.This review summarizes recent studies on the JAK-STAT signaling pathway and its inhibitors.